Sign inCreate account

Report workspace tools

NCT06943677RECRUITINGanonymous

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsules in Subjects With Advanced Malignant Tumors

Sponsor

Source record

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase

Source record

PHASE1

Modality

AI-normalized

protein therapy

Target

AI-normalized

TQB3019 capsules

Indication / condition

AI-normalized

Advanced Malignant Cancer

Intervention

Source record

TQB3019 capsules

Source & freshness

Source record

NCT ID

NCT06943677

Original source

ClinicalTrials.gov

Source last updated

Feb 12, 2026

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06943677

Title

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsules in Subjects With Advanced Malignant Tumors

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Status

RECRUITING

Phase

PHASE1

Condition raw

Advanced Malignant Cancer

Condition normalized

Advanced Malignant Cancer

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

TQB3019 capsules

Target normalized

TQB3019 capsules

Interventions

TQB3019 capsules

Public preview

Source record

The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3019 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3019 capsules.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsules in Subjects With Advanced Malignant Tumors

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06943677

Status

RECRUITING

Phase

PHASE1

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Executive brief

Investment-Ready Snapshot

The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3019 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3019 capsules.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 12, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06943677

Indication

Advanced Malignant Cancer

Modality

protein therapy

Target

TQB3019 capsules

Intervention

TQB3019 capsules

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.